Obsidian Therapeutics
Obsidian Therapeutics raises $160.5M Series C at $750M valuation
Quick Facts
Obsidian Therapeutics: Series C Funding Round
Obsidian Therapeutics has successfully raised $160.5M in Series C funding, reaching a valuation of $750M.
Company Overview
Clinical-stage biotech developing cell and gene therapies for cancer
Funding Details
The Series C round was led by New Enterprise Associates, with participation from Vida Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2014
- Employees: 100+
- Category: Biotech
Investment
Obsidian Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series C
- Vida Ventures: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...